We are live on ! Find out more
AIM

AIM ImmunoTech
AIM

35 hedge funds and large institutions have $1.67M invested in AIM ImmunoTech in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

3% more funds holding

Funds holding: 34 → 35 (+1)

29% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 7

50% less capital invested

Capital invested by funds: $3.36M → $1.67M (-$1.69M)

Holders
35
Holders Change
+1
Holders Change %
+2.94%
% of All Funds
0.56%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
5
Reduced
7
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$32.7K
2
UBS Group
UBS Group
Switzerland
+$10.8K
3
TSS
Two Sigma Securities
New York
+$6.69K
4
Renaissance Technologies
Renaissance Technologies
New York
+$5.58K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$2.37K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$224K
2
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
-$12K
3
LPL Financial
LPL Financial
California
-$9K
4
Millennium Management
Millennium Management
New York
-$5.2K
5
VF
Virtu Financial
New York
-$3.72K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$620K +$511 +11 +0.1%
Morgan Stanley
2
Morgan Stanley
New York
$286K -$224K -4,822 -34%
BlackRock
3
BlackRock
New York
$254K +$93 +2 +0%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$118K -$511 -11 -0.3%
State Street
5
State Street
Massachusetts
$54K – – –
Verition Fund Management
6
Verition Fund Management
Connecticut
$47.7K – – –
BCM
7
Bridgeway Capital Management
Texas
$47.1K – – –
Renaissance Technologies
8
Renaissance Technologies
New York
$43K +$5.58K +120 +10%
T. Rowe Price Associates
9
T. Rowe Price Associates
Maryland
$36K – – –
Northern Trust
10
Northern Trust
Illinois
$27K – – –
Citadel Advisors
11
Citadel Advisors
Florida
$21.9K +$32.7K +703 New
Cambridge Investment Research Advisors
12
Cambridge Investment Research Advisors
Iowa
$15K -$232 -5 -1%
Rockefeller Capital Management
13
Rockefeller Capital Management
New York
$12K – – –
SWM
14
SeaCrest Wealth Management
New York
$11.6K -$1.39K -30 -7%
RJFSA
15
Raymond James Financial Services Advisors
Florida
$11.5K – – –
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$10.6K +$2.37K +51 +18%
VF
17
Virtu Financial
New York
$10K -$3.72K -80 -20%
UBS Group
18
UBS Group
Switzerland
$9.07K +$10.8K +232 +380%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$7.88K – – –
FWM
20
ForthRight Wealth Management
Georgia
$6.24K – – –
Millennium Management
21
Millennium Management
New York
$6K -$5.2K -112 -38%
TSS
22
Two Sigma Securities
New York
$4.5K +$6.69K +144 New
CB
23
Community Bank
New York
$4.1K – – –
TCM
24
Traynor Capital Management
Pennsylvania
$3.67K – – –
SFG
25
SNS Financial Group
Minnesota
$3.12K – – –
1
2

AIM Hedge Fund Activity: Q4 2022 in Review

35 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q4 2022, worth a combined $1.67M — down 50% from $3.36M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new AIM positions and 3 closed out — a net gain of 2 holders — while 5 added to existing stakes and 7 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $32.7K. The largest seller was Morgan Stanley, cutting an estimated $224K.

  • 35 institutional investors held AIM ImmunoTech (AIM) as of Q4 2022, up from 34 in Q3 2022.
  • Funds reported $1.67M of AIM ImmunoTech stock for Q4 2022, down 50% quarter-over-quarter.
  • 5 funds opened new AIM ImmunoTech positions in Q4 2022 and 3 closed out, a net change of +2 holders.
  • The largest AIM ImmunoTech buyer in Q4 2022 was Citadel Advisors, an estimated $32.7K added.
  • The largest AIM ImmunoTech seller in Q4 2022 was Morgan Stanley, an estimated $224K sold.

Based on aggregated 13F filings for Q4 2022.